Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 181
Medical Isotope Production without Highly Enriched Uranium Appendix C Presentations and Visits WASHINGTON, D.C., FEBRUARY 15–16, 2007 Department of Energy-National Nuclear Security Administration, Office of Global Threat Reduction, Nicole Nelson-Jean, DOE-NNSA, Office of North and South American Threat Reduction; Parrish Staples, DOE-NNSA, Office of Global Threat Reduction Initiatives for the Development of Commercially Viable Mo-99 Production Methods Using LEU, Roy W. Brown, Council on Radionuclides and Radiopharmaceuticals (CORAR) Conversion of Molybdenum-99 (Mo-99) Production to LEU Target Technology, Grant Malkoske, MDS-Nordion OPAL (Open Pool Australian Lightwater) Reactor and Molybdenum-99, Therese Donlevy, Australian Nuclear Science and Technology Organisation (ANSTO) Mallinckrodt’s Approach to HEU to LEU Conversion, Richard A. Roberts, Tyco Health Care/Mallinckrodt The Security Imperative of Eliminating Commercial Use of HEU, Ed S. Lyman, Union of Concerned Scientists Cost of Converting from HEU to LEU Targets for Medical Radioisotope Production, Frank von Hippel, Princeton University IAEA Input to NAS Study on Medical Radioisotope Production without HEU, Ira Goldman, International Atomic Energy Agency (IAEA)
OCR for page 182
Medical Isotope Production without Highly Enriched Uranium WASHINGTON, D.C., APRIL 10–11, 2007 ANL Perspective on Conversion of Mo-99 Production from High to Low Enriched Uranium, George Vandegrift, Argonne National Laboratory (ANL) Commercial Production of Fission Mo-99 from LEU Targets in Argentina, Pablo Cristini and Marcelo Salvatore, Comisión Nacional de Energia Atómica (CNEA) and INVAP (Investigaciones Aplicadas Sociedad del Estado) Commercial Production of Fission Radioisotopes from LEU Targets in Argentina, Pablo Cristini, CNEA FDA’s Regulatory Role in Medical Isotope Production, Orhan Suleiman, Food and Drug Administration (FDA) NRC’s Process for Licensing Exports of Highly Enriched Uranium (HEU) Medical Isotope Target Material, Stephen Dembek, U.S. Nuclear Regulatory Commission (NRC) Highly Enriched Uranium (HEU) Exports for Medical Isotope Production, Edward T. Fei, NNSA Conversion of Molybdenum-99 (Mo-99) Production to LEU Target Technology, Grant Malkoske, MDS Nordion Mallinckrodt’s Mo-99 Process & Progress to LEU Conversion, Dale Simpson, Tyco Healthcare/Mallinckrodt Ion Beam Applications: Past, Present, and Future, Henri Bonet, Institute National des Radioéléments (IRE) WASHINGTON, D.C., JUNE 11–12, 2007 Global Threat Reduction Initiative–Reactor Conversion Program– Molybdenum-99 Production with LEU, Parrish Staples, DOE-NNSA Drug Master File Development and FDA Filings for LEU-Produced Medical Radionuclides, Roy Brown, CORAR Cardinal Health Nuclear Pharmacy Services, Jack Coffey, Cardinal Health The Cost of Developing Imaging Agents for Routine Clinical Use, Adrian Nunn, Bracco Research Status of IAEA Mo-99 Activities, Ira Goldman, IAEA National Academy of Sciences: Medical Isotope Production Study, Ralph Butler, University of Missouri Research Reactor (MURR) AECL’s Medical Isotope Production, Brian McGee, Atomic Energy of Canada Limited (AECL)
OCR for page 183
Medical Isotope Production without Highly Enriched Uranium ST. LOUIS, MISSOURI, OCTOBER 15–17, 2007 Supporting the Nation’s Nuclear Medicine Research–Update, Ralph A. Butler, MURR Efforts by Current Commercial Mo-99 Producers to Examine LEU Technologies, Roy W. Brown, CORAR SITE VISITS August 20–21, 2007: Visit to AECL Chalk River Laboratories (Chalk River, Ontario, Canada) and MDS Nordion (Kanata, Ontario, Canada) December 17–18, 2007: Visit to ANSTO (Lucas Heights, Australia) March 10–12, 2008: Visit to IRE (Fleures, Belguim), CERCA (Romans, France) and Mallinckrodt (Petten, the Netherlands) June 5–6, 2008: Visit to CNEA (Buenos Aires, Argentina)